| "Helping women track their ovulation in a smarter way" | 
Male first-degree relatives of women with PMOS show higher rates of metabolic and hormonal differences than comparison groups, which researchers describe as a possible “male equivalent.” There are no diagnostic criteria for it and it is not a recognized diagnosis. The concept describes a familial pattern under investigation, not a condition anyone is currently diagnosed with.
Key takeaways
- Fathers and brothers of women with polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) show higher rates of certain metabolic and hormonal differences than comparison groups.
- Researchers describe this as a possible “male equivalent”, but there are no diagnostic criteria for it and it is not a recognized diagnosis.
- The concept was one of the reasons two participants in the renaming consensus objected to a name containing “ovarian”.
- The evidence is consistent on the metabolic side and unsettled on parts of the hormonal picture.
- Nothing here is something a man can use to identify himself as having anything.
Where does this idea come from?
From studies of the male relatives of women who have the condition.
PMOS has familial and genetic components, and that raises an obvious question: if a set of metabolic and hormonal traits runs in families, what does it look like in family members who do not have ovaries?
The question also surfaced in the renaming process itself. Two workshop participants were unsupportive of the change, and one of their stated reasons was the potential for a male phenotype: a name containing “ovarian” does not accommodate that possibility.1 Our article on what the dissenting researchers objected to covers the objections in full.
What does the research actually show?
21 studies. A systematic review and meta-analysis of 21 studies examined male first-degree relatives (fathers and brothers) of women with the condition (DOI: 10.1186/s12610-025-00290-1).2
Compared with control groups, those relatives showed higher fasting blood glucose, body mass index, triglycerides, total cholesterol, LDL cholesterol and dehydroepiandrosterone sulfate.2 They also showed a higher prevalence of hypertension, larger waist circumference, and early pattern hair loss.2 Findings were consistent across studies, with low to moderate heterogeneity.2
The authors’ conclusion is careful: the results support the concept of a male equivalent, while the condition remains without clear diagnostic criteria.2
What is still unsettled
The hormonal side, more than the metabolic side.
A separate review describes the hormonal and metabolic profile as still controversial, and notes there is no consensus on whether the proposed phenotype is associated with hypertension and obesity.3 That sits in tension with the meta-analysis above, which did find higher hypertension prevalence.
| Meta-analysis | Separate review |
|---|---|
| Higher hypertension prevalence | No consensus on hypertension and obesity |
Reduced sex hormone-binding globulin appears in both accounts, with increased free androgens alongside typical or lower total testosterone.3 That is the same paradox seen in women, where symptoms of androgen excess coexist with a total testosterone result in the reference range. Our article on why androgen symptoms vary between people covers that mechanism.
Two reviews of the same literature reaching different conclusions on the same question is what an unsettled area looks like. It is worth knowing when you encounter confident claims in either direction.
What this does not mean
Three things, stated plainly.
- There is no diagnosis to receive. No diagnostic criteria exist, and no clinician diagnoses a male equivalent of this condition. Descriptions of a phenotype in research are not the same as a condition in a clinic.
- Early pattern hair loss is not a test. It appears in this literature as a statistical association within a studied group. Pattern hair loss is extremely common and has many causes. It identifies nothing about an individual.
- A relative having PMOS does not tell you what your own health is. These are group findings about populations of relatives. They do not translate into a statement about any particular person.
Why it matters anyway
Because it is one of the genuinely open questions about this condition, and because the name depends on it.
If a related phenotype exists in men, “ovarian” describes where it shows up in half the people who carry it rather than what it fundamentally is. That was the dissenting participants’ point,1 and it is a reasonable one whether or not the research eventually supports it.
It also matters for how the condition is understood. A familial endocrine and metabolic pattern is a different kind of thing from an ovarian disorder, and which of those it turns out to be shapes what gets studied next.
What this means for tracking with Premom
Nothing in this article relates to anything the app tracks. It is included because it is one of the open questions behind the new name, not because it connects to a product.
Premom is an ovulation tracking application. It is not intended to diagnose, treat, cure, or prevent any disease, including PMOS. The information provided is for educational purposes and should not replace consultation with a healthcare provider.
When to talk to a clinician
Anyone with concerns about their own metabolic or hormonal health should raise them with a clinician, whether or not a relative has this diagnosis. Questions about family history are reasonable to ask and a clinician can put them in context.
Nothing in this article is a reason to request a specific test or to conclude anything about your own health.
Frequently asked questions
No. PMOS is currently defined and diagnosed in individuals with female reproductive physiology. Researchers are investigating whether a related phenotype exists in men.
It might be, and it might not. Studies of male first-degree relatives show higher rates of certain metabolic differences as a group (DOI: 10.1186/s12610-025-00290-1), but a group finding does not establish a cause for any individual. His clinician is the right person to ask.
No. Early pattern hair loss appears in this research as a statistical association within studied groups. It is common, it has many causes, and it identifies nothing about an individual.
That is a question for a clinician who knows their history. This article deliberately makes no screening recommendation, because no diagnostic criteria exist for what would be screened for.
It is one of three stated reasons two workshop participants gave for opposing the renaming, alongside evolving science on the genetic component and concerns about rebranding.
About PMOS
Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) by international consensus published in The Lancet on 12 May 2026.1 A three-year transition runs to 2028, and both names remain in clinical use. Diagnostic criteria did not change, and an existing PCOS diagnosis remains valid.
Reported prevalence varies with the criteria applied; the 2023 International Evidence-Based Guideline reports 10–13% (DOI: 10.1210/clinem/dgad463).4
References
- Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online 12 May 2026. DOI 10.1016/S0140-6736(26)00717-8 · PMID 42119588. CC BY 4.0.
- Male polycystic ovarian syndrome phenotype: a meta-analysis of endocrine-metabolic dysregulation in fathers and brothers of PCOS-affected women. Basic Clin Androl. DOI 10.1186/s12610-025-00290-1 · PMID 41243102 · PMCID PMC12621411.
- Male equivalent polycystic ovarian syndrome: hormonal, metabolic and clinical aspects. PMCID PMC7382675.
- Teede HJ, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. DOI 10.1210/clinem/dgad463 · PMID 37580314.
